New drug extends life in advanced uterine cancer, a win for women’s cancers

If you or someone you love has been touched by one of the women’s cancers, here is news worth sharing. A new medicine helped women with advanced uterine cancer live longer, even after the usual treatments had stopped working.

The drug is called sacituzumab tirumotecan, or sac-TMT for short. In a large trial, women who got it lived longer than women who got standard chemotherapy. That is a real gain in a cancer that has had very few good options.

How the study worked

This was a phase 3 trial, the kind doctors use to decide on new standard care. It enrolled 776 women with advanced or recurrent endometrial cancer at 242 centers in 31 countries and regions. All of them had already been treated with platinum-based chemotherapy and immunotherapy, and the cancer had kept growing. A computer assigned each woman by chance to sac-TMT or to the doctor’s choice of chemotherapy (doxorubicin or paclitaxel). Doctors and patients knew which treatment was given, but the radiologists who judged the scans did not. The results were published Oct. 26, 2026, in The Lancet, and the trial is still going.

What they found

Women on sac-TMT lived longer than women on standard chemotherapy. That was the main result of the trial.

The drug also held the cancer back for longer. The time before the cancer grew again was clearly longer on sac-TMT than on standard chemotherapy.

Side effects were part of the picture, as they are with most cancer drugs. Serious side effects were reported in 35% of women on sac-TMT and 32% on standard chemotherapy, which is close. Deaths linked to treatment were rare and the same in both groups: three women in each.

The researchers concluded that these results support sac-TMT as a new standard of care for women whose endometrial cancer has progressed after chemotherapy and immunotherapy.

What is sac-TMT?

Think of it as a guided delivery truck. Cancer cells often carry a marker on their surface called TROP2. Sac-TMT has an antibody that finds that marker and carries a strong cancer-fighting drug straight to the tumor cells. This type of medicine is called an antibody-drug conjugate.

What you can do today

If you or someone close to you has endometrial cancer that grew after chemotherapy and immunotherapy, write down one question for the oncologist: “Is a TROP2-targeted drug like sac-TMT, or a clinical trial, an option for me?” You can search for open trials at ClinicalTrials.gov, the free US government database. This trial is listed there as NCT06132958.